المؤلفون: Wen, Ruishan, Huang, Xiulian, Long, Jinyu, Guo, Yuxin, Wei, Yilun, Lin, Ping, Xie, Siting, Zhao, Zhongquan, Zhang, Lei, Fan, Arthur Yin, Barbalho, Sandra M, Nardone, Valerio, Alzeer, Jawad, Chen, Ying, Yu, Zongyang

المصدر: Wen, Ruishan; Huang, Xiulian; Long, Jinyu; Guo, Yuxin; Wei, Yilun; Lin, Ping; Xie, Siting; Zhao, Zhongquan; Zhang, Lei; Fan, Arthur Yin; Barbalho, Sandra M; Nardone, Valerio; Alzeer, Jawad; Chen, Ying; Yu, Zongyang (2024). Advances in traditional Chinese herbal medicine and their pharmacodynamic mechanisms in cancer immunoregulation: a narrative review. Translational Cancer Research, 13(2):1166-1187.

مصطلحات موضوعية: 540 Chemistry, Cancer Research, Radiology, Nuclear Medicine and imaging, Oncology

الوصف: Background and Objective: The cancer-immunity cycle (CIC) is defined as a series of progressive events that cause an anticancer immune response leading to the killing of the cancer cell. The concept of CIC has important guiding significance for the clinical and basic tumor immunotherapy research. As one of the methods of traditional Chinese medicine (TCM), Chinese herbal medicine (CHM) has shown unique advantages in multitarget and multipathway immune regulation. However, the tumor immune circulation targeted by CHM is generally unclear at present. To provide reference for future clinical and basic research, we systematically reviewed the existing literature on CHM (including CHM monomers, CHM compounds, and CHM patent medicines) and the mechanisms related to its efficacy. Methods: We searched the PubMed and China National Knowledge Infrastructure (CNKI) databases for relevant Chinese-language and English-language literature published from January 1988 to October 2022. The literature was screened manually at three levels: title, abstract, and full text, to identify articles related to CHM and their mechanism of regulating tumor immunity. Key Content and Findings: By further classifying the CIC, it was confirmed that CHM can regulate the activation of dendritic cells (DCs) and macrophages and promote the presentation of tumor antigens. Meanwhile, CHM can also reverse tumor-immune escape by enhancing T-cell proliferation and infiltration. In addition, CHM can also enhance the antitumor ability of the body by regulating the killing process of tumor cells. Conclusions: The theory of a CIC is of guiding significance to regulating tumor immunity via CHM

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/257549/1/82623_PB4_5720_R2.pdfTest; urn:issn:2218-676X

الإتاحة: https://doi.org/10.5167/uzh-25754910.21037/tcr-23-1983Test
https://www.zora.uzh.ch/id/eprint/257549Test/
https://www.zora.uzh.ch/id/eprint/257549/1/82623_PB4_5720_R2.pdfTest

المؤلفون: Ciammella, Patrizia, Cozzi, Salvatore, Borghetti, Paolo, Galaverni, Marco, Nardone, Valerio, Ruggieri, Maria Paola, Sepulcri, Matteo, Scotti, Vieri, Bruni, Alessio, Zanelli, Francesca, Piro, Roberto, Tagliavini, Elena, Botti, Andrea, Iori, Federico, Alì, Emanuele, Bennati, Chiara, Tiseo, Marcello

المصدر: Frontiers in Oncology ; volume 14 ; ISSN 2234-943X

مصطلحات موضوعية: Cancer Research, Oncology

الوصف: Background Chemoradiation therapy (CRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell death 1 (PD1) axis inhibitors with radiotherapy are in development for patients with LA-NSCLC. However, the effect of CRT on tumor cells programmed cell death ligand-1 (PD-L1) expression is unknown. Methods In this multicentric retrospective study, we analyzed paired NSCLC specimens that had been obtained pre- and post-CRT. PD-L1 expression on tumor cells was studied by immunohistochemistry. The purpose of this study was to evaluate the feasibility, risk of complications, and clinical relevance of performing re-biopsy after CRT in patients with PD-L1 negative LA-NSCLC. Results Overall, 31 patients from 6 centers with PD-L1 negative LA-NSCLC were analyzed. The percentage of tumor cells with PD-L1 expression significantly increased between pre- and post-CRT specimens in 14 patients (45%). Nine patients had unchanged PD-L1 expression after CRT, in five patients the rebiopsy material was insufficient for PD-L1 analysis and in two patients no tumor cells at rebiopsy were found. The post-rebiopsy complication rate was very low (6%). All patients with positive PD-L1 re-biopsy received Durvalumab maintenance after CRT, except one patient who had a long hospitalization for tuberculosis reactivation. Median PFS of patients with unchanged or increased PD-L1 expression was 10 and 16.9 months, respectively. Conclusion CRT administration can induce PD-L1 expression in a considerable fraction of PD-L1 negative patients at baseline, allowing them receiving the maintenance Durvalumab in Europe. Hence, after a definitive CRT, PD-L1 redetermination should be considered in patients with LA-NSCLC PD-L1 negative, to have a better selection of maintenance Durvalumab candidates.

الإتاحة: https://doi.org/10.3389/fonc.2024.1325249Test

المؤلفون: Gagliardi, Federico, Russo, Anna, Scharf, Camila, Pinto, Alessandro, Faenza, Mario, D'Ippolito, Emma, Argenziano, Giuseppe, Troiani, Teresa, Reginelli, Alfonso, Nardone, Valerio

المصدر: Clinical and Translational Radiation Oncology ; volume 46, page 100774 ; ISSN 2405-6308

مصطلحات موضوعية: Radiology, Nuclear Medicine and imaging, Oncology

الإتاحة: https://doi.org/10.1016/j.ctro.2024.100774Test
https://api.elsevier.com/content/article/PII:S240563082400051X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S240563082400051X?httpAccept=text/plainTest

المؤلفون: Gagliardi, F., Nardone, V., Grassi, R., Belfiore, M., Roccatagliata, P., Buono, M., Cimmino, G., Della Corte, C.M., Morgillo, F., Ciardiello, F., Reginelli, A., Cappabianca, S.

المصدر: ESMO Open ; volume 9, page 102737 ; ISSN 2059-7029

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.102737Test
https://api.elsevier.com/content/article/PII:S2059702924005052?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702924005052?httpAccept=text/plainTest

المؤلفون: Gaetano Maria Russo, Anna Russo, Fabrizio Urraro, Fabrizio Cioce, Luigi Gallo, Maria Paola Belfiore, Angelo Sangiovanni, Stefania Napolitano, Teresa Troiani, Pasquale Verolino, Antonello Sica, Gabriella Brancaccio, Giulia Briatico, Valerio Nardone, Alfonso Reginelli

المصدر: Diagnostics; Volume 13; Issue 4; Pages: 793

مصطلحات موضوعية: dermatology, high-frequency ultrasound, MDT, skin cancer, radiotherapy, melanoma, oncology, ultrasound, computed tomography, magnetic resonance imaging

الوصف: Basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma are the three main types of nonmelanoma skin cancers and their rates of occurrence and mortality have been steadily rising over the past few decades. For radiologists, it is still difficult to treat patients with advanced nonmelanoma skin cancer. Nonmelanoma skin cancer patients would benefit greatly from an improved diagnostic imaging-based risk stratification and staging method that takes into account patient characteristics. The risk is especially elevated among those who previously received systemic treatment or phototherapy. Systemic treatments, including biologic therapies and methotrexate (MTX), are effective in managing immune-mediated diseases; however, they may increase susceptibility to NMSC due to immunosuppression or other factors. Risk stratification and staging tools are crucial in treatment planning and prognostic evaluation. PET/CT appears more sensitive and superior to CT and MRI for nodal and distant metastasis as well as in surveillance after surgery. The patient treatment response improved with advent and utilization of immunotherapy and different immune-specific criteria are established to standardized evaluation criteria of clinical trials but none of them have been utilized routinely with immunotherapy. The advent of immunotherapy has also arisen new critical issues for radiologists, such as atypical response pattern, pseudo-progression, as well as immune-related adverse events that require early identification to optimize and improve patient prognosis and management. It is important for radiologists to have knowledge of the radiologic features site of the tumor, clinical stage, histological subtype, and any high-risk features to assess immunotherapy treatment response and immune-related adverse events.

وصف الملف: application/pdf

العلاقة: Medical Imaging and Theranostics; https://dx.doi.org/10.3390/diagnostics13040793Test

الإتاحة: https://doi.org/10.3390/diagnostics13040793Test

المؤلفون: de Rosa, C., Tuccillo, C., Amato, L., Ciardiello, F., Nardone, V., Morgillo, F., Della Corte, C.M.

المصدر: Immuno-Oncology and Technology ; volume 20, page 100627 ; ISSN 2590-0188

مصطلحات موضوعية: Oncology, Immunology and Allergy

الإتاحة: https://doi.org/10.1016/j.iotech.2023.100627Test
https://api.elsevier.com/content/article/PII:S2590018823002903?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2590018823002903?httpAccept=text/plainTest

المؤلفون: Nardone, A., Morrison-Thiele, G., Goldstein, A., De Angelis, C., Veeraraghavan, J., Fu, X., Liu, C.C., Wang, T., Shea, M., Cosulich, S., Davies, B., Tsimelzon, A., Huang, S., Chamness, G., Jeselsohn, R., Malorni, L., Rimawi, M., Hilsenbeck, S., Osborne, C.K., Schiff, R.

المصدر: ESMO Open ; volume 8, issue 1, page 101267 ; ISSN 2059-7029

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.esmoop.2023.101267Test
https://api.elsevier.com/content/article/PII:S2059702923004933?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702923004933?httpAccept=text/plainTest

المؤلفون: Pacifico, Pietro, Colciago, Riccardo Ray, De Felice, Francesca, Boldrini, Luca, Salvestrini, Viola, Nardone, Valerio, Desideri, Isacco, Greco, Carlo, Arcangeli, Stefano

المساهمون: Università degli Studi di Milano - Bicocca

المصدر: Medical Oncology ; volume 39, issue 12 ; ISSN 1559-131X

مصطلحات موضوعية: Cancer Research, Oncology, Hematology, General Medicine

الوصف: Since the first definition by Hellman and Weichselbaum in 1995, the concept of OligoMetastatic Disease (OMD) is a growing oncology field. It was hypothesized that OMD is a clinical temporal window between localized primary tumor and widespread metastases deserving of potentially curative treatment. In real-world clinical practice, OMD is a “spectrum of disease” that includes a highly heterogeneous population of patients with different prognosis. Metastasis directed therapy with local ablative treatment have proved to be a valid alternative to surgical approach. Stereotactic body radiation therapy demonstrated high local control rate and increased survival outcomes in this setting with a low rate of toxicity. However, there is a lack of consensus regarding many clinical, therapeutic, and prognostic aspects of this disease entity. In this review, we try to summarize the major critical features that could drive radiation oncologists toward a better selection of patients, treatments, and study endpoints. With the help of a set of practical questions, we aim to integrate the literature discussion.

الإتاحة: https://doi.org/10.1007/s12032-022-01788-8Test

المؤلفون: Fameli, Antonella, Nardone, Valerio, Shekarkar Azgomi, Mojtaba, Bianco, Giovanna, Gandolfo, Claudia, Oliva, Bianca Maria, Monoriti, Marika, Saladino, Rita Emilena, Falzea, Antonella, Romeo, Caterina, Calandruccio, Natale Daniele, Azzarello, Domenico, Giannicola, Rocco, Pirtoli, Luigi, Giordano, Antonio, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Cusi, Maria Grazia, Mutti, Luciano, Botta, Cirino, Correale, Pierpaolo

المصدر: Frontiers in Oncology ; volume 12 ; ISSN 2234-943X

مصطلحات موضوعية: Cancer Research, Oncology

الوصف: Peripheral immune-checkpoint blockade with mAbs to programmed cell death receptor-1 (PD-1) (either nivolumab or pembrolizumab) or PD-Ligand-1 (PD-L1) (atezolizumab, durvalumab, or avelumab) alone or in combination with doublet chemotherapy represents an expanding treatment strategy for metastatic non-small cell lung cancer (mNSCLC) patients. This strategy lays on the capability of these mAbs to rescue tumor-specific cytotoxic T lymphocytes (CTLs) inactivated throughout PD-1 binding to PD-L1/2 in the tumor sites. This inhibitory interactive pathway is a physiological mechanism of prevention against dangerous overreactions and autoimmunity in case of prolonged and/or repeated CTL response to the same antigen peptides. Therefore, we have carried out a retrospective bioinformatics analysis by single-cell flow cytometry to evaluate if PD-1/PD-L1-blocking mAbs modulate the expression of specific peripheral immune cell subsets, potentially correlated with autoimmunity triggering in 28 mNSCLC patients. We recorded a treatment-related decline in CD4 + T-cell and B-cell subsets and in the neutrophil-to-lymphocyte ratio coupled with an increase in natural killer T (NKT), CD8 + PD1 + T cells, and eosinophils. Treatment-related increase in autoantibodies [mainly antinuclear antibodies (ANAs) and extractable nuclear antigen (ENA) antibodies] as well as the frequency of immune-related adverse events were associated with the deregulation of specific immune subpopulations (e.g., NKT cells). Correlative biological/clinical studies with deep immune monitoring are badly needed for a better characterization of the effects produced by PD-1/PD-L1 immune-checkpoint blockade.

الإتاحة: https://doi.org/10.3389/fonc.2022.911579Test

المؤلفون: Della Corte, C.M., Ciaramella, V., Nardone, V., Di Guida, G., Ciardiello, F., Morgillo, F.

المصدر: Immuno-Oncology and Technology ; volume 16, page 100233 ; ISSN 2590-0188

مصطلحات موضوعية: Oncology, Immunology and Allergy

الإتاحة: https://doi.org/10.1016/j.iotech.2022.100233Test
https://api.elsevier.com/content/article/PII:S2590018822001642?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2590018822001642?httpAccept=text/plainTest